Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

British Journal of Haematology

Volumn 143, Issue 3, 2008, Pages 369-373

  Lebovic, D ^a   Hoffman, J ^b   Levine, B M ^b   Hassoun, H ^b   Landau, H ^b   Goldsmith, Y ^b   Maurer, M S ^c   Steingart, R M ^b   Cohen, A D ^b   Comenzo, R L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Amyloidosis; Immunoglobulin light chains; Melphalan

Indexed keywords

CIPROFLOXACIN; DEXAMETHASONE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PROTON PUMP INHIBITOR; THALIDOMIDE; TROPONIN I;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG FATALITY; FEMALE; HEART AMYLOIDOSIS; HEART VENTRICLE SEPTUM; HEMATOLOGICAL PARAMETERS; HUMAN; KIDNEY FUNCTION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEX DIFFERENCE; STEM CELL TRANSPLANTATION; SURVIVAL; SURVIVAL TIME; SYSTEMIC LIGHT CHAIN AMYLOIDOSIS; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CARDIOMYOPATHIES; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; PROGNOSIS; SEX FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 54049148697     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07327.x     Document Type: Article

References (12)

1. Cohen, A.D., Zhou, P., Chou, J., Teruya-Feldstein, J., Reich, L., Hassoun, H., Levine, B., Filippa, D.A., Riedel, E., Kewalramani, T., Stubblefield, M.D., Fleisher, M., Nimer, S. Comenzo, R.L. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal Haematology, 139, 224 233.
2. Comenzo, R.L., Sanchorawala, V., Fisher, C., Akpek, G., Farhat, M., Cerda, S., Berk, J.L., Dember, L.M., Falk, R., Finn, K., Skinner, M. Vosburgh, E. (1999) Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM + G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Haematology, 104, 553 559.
3. Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Rajkumar, S.V., Fonseca, R., Zeldenrust, S.R., McGregor, C.G. Jaffe, A.S. (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology, 22, 3751 3757.
4. Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465 470.
5. Falk, R.H., Comenzo, R.L. Skinner, M. (1997) The systemic amyloidoses. New England Journal of Medicine, 337, 898 909.
6. Kastritis, E., Anagnostopoulos, A., Roussou, M., Toumanidis, S., Pamboukas, C., Migkou, M., Tassidou, A., Xilouri, I., Delibasi, S., Psimenou, E., Mellou, S., Terpos, E., Nanas, J. Dimopoulos, M.A. (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 92, 1351 1358.
7. Maurer, M.S., Raina, A., Hesdorffer, C., Bijou, R., Colombo, P., Deng, M., Drusin, R., Haythe, J., Horn, E., Lee, S.H., Marboe, C., Naka, Y., Schulman, L., Scully, B., Shapiro, P., Prager, K., Radhakrishnan, J., Restaino, S. Mancini, D. (2007) Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation, 83, 539 545.
8. Merlini, G. Stone, M.J. (2006) Dangerous small B-cell clones. Blood, 108, 2520 2530.
9. Pepys, M.B. (2006) Amyloidosis. Annual Review of Medicine, 57, 223 241.
10. Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Finn, K.T., Dember, L.M., Berk, J.L., Quillen, K., Anderson, J.J., Comenzo, R.L. Skinner, M. (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 33, 381 388.
11. Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N. Gillmore, J.D. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457 464.
12. Zhou, P., Comenzo, R.L., Olshen, A.B., Bonvini, E., Koenig, S., Maslak, P.G., Fleisher, M., Hoffman, J., Jhanwar, S., Young, J.W., Nimer, S.D. Boruchov, A.M. (2008) CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood, 111, 3403 3406.